Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company focused on developing genetic medicines for rare neurological diseases, has announced the approval of non-qualified stock options as part of its new compensation plan. These options, known as Inducement Grants, were issued to four new employees as of June 5, 2025, under the company's 2025 Inducement Plan. The grants, aligned with Nasdaq Listing Rule 5635(c)(4), allow the purchase of a total of 39,345 shares of Neurogene's common stock at the closing price on the grant date. Vesting of these options occurs over four years, with an initial 25 percent vesting after the first year and the remainder in equal portions every three months, contingent upon ongoing employment with the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.